Cannabidiol isolate is under clinical development by Canopy Growth and currently in Phase II for Menstrual Disorders. According to GlobalData, Phase II drugs for Menstrual Disorders have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol isolate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol isolate overview

Cannabidiol isolate is under development for the treatment of menstrual-related symptoms. The drug candidate is administered through oral route in the form of softgels and acts by targeting cannabinoid receptors CB1 and CB2.

Canopy Growth overview

Canopy Growth, a subsidiary of Constellation Brands Inc, is a cannabis company that carries the production, distribution and marketing of a range of cannabis and hemp-based products for medical and recreational businesses. The company offers cannabis products including curated cannabis varieties including soft gel capsules, dried cannabis flowers, vapes, and edibles. beverages, oils and concentrates and cannabis accessories. Canopy Growth also provides hemp-derived CBD products such as topical creams, oils and soft gels and nutrition beverages. The company markets products under various brand names including Tweed, Spectrum Therapeutics, Martha Stewart, Tokyo Smoke, Deep Space, Quatreau, Simple Stash, Twd, DNA Genetics, Van der Pop, CraftGrow, and DOJA. It has operations in Canada, the United States, Germany, Australia, the United Kingdom, Denmark, Brazil and Peru. Canopy Growth is headquartered in Smiths Falls, Ontario, Canada.

For a complete picture of Cannabidiol isolate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.